{
  "name": "Telmisartan",
  "category": "pharmaceutical",
  "evidenceGrade": "B",
  "riskProfile": "medium",
  "description": "Angiotensin II receptor blocker (ARB) with unique PPAR-γ partial agonist activity. Beyond blood pressure control, activates metabolic pathways similar to caloric restriction. Among the longest-acting ARBs with 24hr coverage. Popular in longevity medicine even for normotensive individuals.",
  "mechanisms": [
    "Angiotensin II receptor blockade",
    "PPAR-γ partial agonism (metabolic benefits)",
    "Insulin sensitivity improvement",
    "Anti-inflammatory and antifibrotic"
  ],
  "dosage": {
    "standard": "20-40mg/day",
    "range": "20-80mg/day",
    "notes": "Prescription required. Unique among ARBs for PPAR-γ activation. 24-hour half-life. Can be used at low dose (20mg) even without hypertension. Peter Attia protocols mention it."
  },
  "keyFindings": [
    "ONTARGET trial: comparable to ACE inhibitor ramipril for cardiovascular protection",
    "Unique PPAR-γ agonism improves insulin sensitivity — not seen with other ARBs",
    "Reduced new-onset diabetes by 30% compared to other antihypertensives"
  ],
  "interactions": [
    "Potassium supplements (hyperkalemia risk)",
    "NSAIDs (reduced efficacy)",
    "Lithium (increased levels)",
    "Other antihypertensives"
  ],
  "sideEffects": [
    "Dizziness",
    "Hypotension",
    "Hyperkalemia",
    "Back pain"
  ],
  "contraindications": [
    "Pregnancy (teratogenic)",
    "Bilateral renal artery stenosis",
    "Severe hepatic impairment"
  ],
  "tags": [
    "pharmaceutical",
    "arb",
    "metabolic",
    "ppar-gamma",
    "cardiovascular",
    "prescription"
  ],
  "estimatedMonthlyCost": {
    "low": 5,
    "mid": 15,
    "high": 30,
    "currency": "USD"
  },
  "id": "prod-telmisartan",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.815Z",
  "createdAt": "2026-02-04T14:50:14.815Z"
}